{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sabt A"],"funding":["Deanship of Scientific Research at Princess Nourah bint Abdulrahman University"],"pagination":["1616-1630"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7470104"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(1)"],"pubmed_abstract":["Human health in the current medical era is facing numerous challenges, especially cancer. So, the therapeutic arsenal for cancer should be unremittingly enriched with novel small molecules that selectively target tumour cells with minimal toxicity towards normal cells. In this context, herein a new series of 3,6-disubstituted pyridazines <b>11a-r</b> has been synthesised and evaluated for <i>in vitro</i> anticancer activity. They possessed good anti-proliferative action towards human breast cancer T-47D (IC<sub>50</sub> range: 0.43 ± 0.01 - 35.9 ± 1.18 µM) and MDA-MB-231 (IC<sub>50</sub> range: 0.99 ± 0.03 - 34.59 ± 1.13 µM) cell lines, whereas they displayed weak activity against the tested ovarian cancer cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing pyr"],"journal":["Journal of enzyme inhibition and medicinal chemistry"],"pubmed_title":["Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights."],"pmcid":["PMC7470104"],"funding_grant_id":["RGP-1440–0025"],"pubmed_authors":["Elaasser MM","Abdel-Aziz HA","Eldehna WM","Sabt A","Suliman H","Alotaibi OJ","Al-Warhi T"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.","description":"Human health in the current medical era is facing numerous challenges, especially cancer. So, the therapeutic arsenal for cancer should be unremittingly enriched with novel small molecules that selectively target tumour cells with minimal toxicity towards normal cells. In this context, herein a new series of 3,6-disubstituted pyridazines <b>11a-r</b> has been synthesised and evaluated for <i>in vitro</i> anticancer activity. They possessed good anti-proliferative action towards human breast cancer T-47D (IC<sub>50</sub> range: 0.43 ± 0.01 - 35.9 ± 1.18 µM) and MDA-MB-231 (IC<sub>50</sub> range: 0.99 ± 0.03 - 34.59 ± 1.13 µM) cell lines, whereas they displayed weak activity against the tested ovarian cancer cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing pyr","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2026-04-16T23:17:03.956Z","creation":"2025-06-01T03:53:06.614Z"},"accession":"S-EPMC7470104","cross_references":{"pubmed":["32781872"],"doi":["10.1080/14756366.2020.1806259"]}}